PCIB PCI Biotech Holding ASA

PCI Biotech Holding ASA - Annual Report 2023

PCI Biotech Holding ASA - Annual Report 2023

Oslo, Norway, April 26, 2024.

The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website

For further information, please contact:             

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                       

Ronny Skuggedal, CEO, , Mobile:  757



This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments



EN
26/04/2024

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech full year 2024 interim results

PCI Biotech full year 2024 interim results Oslo (Norway), 27 February 2025 – PCI Biotech (OSE: PCIB), today announces its preliminary full year 2024 results. Please find enclosed the interim report and presentation. Highlights review OperationsPCI Biotech’s 2024 development goals were to demonstrate scalability and manufacturing process benefits of the photochemical-based technology (PCL) in viral vector (AAV) manufacturing by advancing the technology into mini benchtop bioreactors, which are considered representative for commercial manufacturing. Recent mini benchtop bioreactor results...

February 27, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Invitation to preliminary full-year 2024 results presenta...

PCI Biotech: Invitation to preliminary full-year 2024 results presentation Oslo, Norway, 25 February 2025 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's full-year 2024 interim report on Thursday 27 February 2025, 08:30am – 09:00am CET (local time).  The presentation will be held as a live webcast available through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made available on and...

February 25, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Employee share option scheme in connection with promotion...

PCI Biotech: Employee share option scheme in connection with promotion of new CSO Oslo, 10 January 2025 - PCI Biotech (OSE: PCIB), today announced that the Board of Directors has granted share options to Morten Luhr who has been promoted to Chief Scientific Officer (CSO) from January 2025. Anders Høgset, former CSO, will commence as Scientific Advisor in a 20% position. In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI B...

January 10, 2025 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Employee share option scheme

PCI Biotech: Employee share option scheme Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.         In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 885,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), a...

September 2, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech first half 2024 interim results

PCI Biotech first half 2024 interim results Oslo (Norway), 28 August 2024 – PCI Biotech (OSE: PCIB), today announces its interim first half 2024 results. Please find enclosed the interim report and presentation.Highlights review OperationsPCI Biotech’s 2024 development goals are to demonstrate scalability and manufacturing process benefits for the photochemical-based technology (PCL) in viral vector manufacturing. Results reported in Q1 2024 from field testing of the technology with a European partner confirmed the potential benefit of applying photochemical methods in...

August 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch